Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

Vasomotor Rhinitis Clinical Trial

Official title:

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00745849
• Other study ID #: Efficacy Esomeprazole NAR
• Status: Completed
• Phase: N/A
• Start date: June 2005
• Est. completion date: March 2008

Study information

• Verified date: June 2019
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to see if high dose esomeprazole (40mg bid) was effective in treating non-allergic rhinitis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• age between 18-80, symptoms of perennial rhinitis, negative epicutaneous skin testing to a panel of common aeroallergens, and ability to speak English

Exclusion Criteria:

• pregnancy or breast-feeding, evidence of positive skin tests to a common aeroallergen, treatment with a proton pump inhibitor within the month prior to enrollment, treatment with any other anti-reflux therapy within the last month on a daily basis or within the last two weeks on an as needed basis, and other gastrointestinal disorders leading to reflux symptoms

Related Conditions & MeSH terms

• Common Cold
• Rhinitis
• Rhinitis, Vasomotor
• Vasomotor Rhinitis

Intervention

Drug:
• esomeprazole
40mg by mouth twice daily
• placebo

Locations

Country	Name	City	State
United States	Clinical Trials Office, Aston Building, UT Southwestern	Dallas	Texas

Sponsors (2)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Nasal Symptom Scores	(1=none, 7=unbearably severe) difference in nasal symptom scores for the average of the last two weeks of each treatment arm	Last two weeks of each treatment arm